20-F/A: Park Ha Biological Technology Faces Significant Net Loss in FY2025

Park Ha Biological Technology Co., Ltd. reported a substantial net loss of $24.36 million for fiscal year 2025, a significant downturn from the previous year's profit, primarily driven by increased general and administrative expenses.

Summary

• Park Ha Biological Technology Co., Ltd. reported a net loss of $24,364,753 for the fiscal year ended October 31, 2025, a significant decrease from a net income of $478,561 in fiscal year 2024.
• Total revenue increased by 6% to $2,524,843 in FY2025, driven by a 43% rise in product sales, but this was offset by a 10% decrease in franchise fees.
• General and administrative expenses surged by over 3,000% to $25,483,541 in FY2025, largely due to a $24 million share-based compensation expense related to equity incentive plans.
• Selling and marketing expenses increased by 73% to $625,289, primarily due to increased payroll, store rental, and promotion costs.
• Research and development expenses saw a significant increase of 549% to $238,184, mainly due to investments in cell therapies and patent expenses.
• The number of franchisees decreased from 45 to 22 by the end of FY2025, reflecting a strategic shift towards quality control and channel optimization, including stricter admission criteria and performance evaluations.
• Cash and cash equivalents increased to $3,787,678 as of October 31, 2025, up from $547,498 in the prior year, primarily due to financing activities.
• The company received a notice from Nasdaq on September 2, 2025, for not meeting the minimum bid price requirement and is working to regain compliance, including considering a share consolidation.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the substantial net loss, significant increase in administrative expenses driven by share-based compensation, and a contraction in the franchise network, alongside Nasdaq compliance concerns.

Positives

• Product sales revenue increased by 43% to $1,014,034 in FY2025, indicating growing demand for the company's products.
• Sales revenue from non-franchisees increased by 51% to $535,760 in FY2025, driven by the addition of two new directly operated stores.
• Gross profit margin for product sales to non-franchisees improved to 96% in FY2025.
• Cash and cash equivalents significantly increased to $3,787,678 as of October 31, 2025, providing improved liquidity.
• The company is actively working to regain compliance with Nasdaq's minimum bid price requirement, indicating a proactive approach to maintaining its listing.

Negatives

• The company reported a substantial net loss of $24,364,753 in FY2025, a significant reversal from the prior year's net income.
• General and administrative expenses increased dramatically by 3,027% to $25,483,541 in FY2025, primarily due to a large share-based compensation expense.
• Franchise fees revenue decreased by 10% to $1,510,809 in FY2025, reflecting a reduction in the number of franchisees.
• The number of franchisees decreased by 51% from 45 to 22 by the end of FY2025 due to a strategic shift and stricter criteria.
• Allowance for expected credit losses increased by 319% for loans to franchisees, indicating increased credit risk.
• The company received a Nasdaq non-compliance notice for minimum bid price, posing a risk to its listing.
• The company has material weaknesses in internal control over financial reporting due to insufficient in-house accounting personnel with U.S. GAAP and SEC reporting knowledge.

Risks

• The company faces significant regulatory risks in China, including potential government intervention, evolving laws on data security, and the need for CSRC filings for future overseas offerings.
• The VIE structure carries inherent risks, including potential invalidation by PRC authorities, which could materially impact operations and securities value.
• The Holding Foreign Companies Accountable Act (HFCAA) poses a risk of delisting if the PCAOB's access to auditors remains restricted.
• Recent greater oversight by the CAC over data security could adversely impact the business and offering.
• The company relies on a limited number of suppliers, making it vulnerable to supply chain disruptions and price fluctuations.
• A significant portion of revenue is derived from a few major customers, posing a risk if demand from these customers decreases.
• The company's ability to manage its franchise network effectively is crucial, and disputes or non-compliance by franchisees could lead to liabilities.
• The company does not maintain business interruption insurance, leaving it exposed to losses from unforeseen events.
• The company's stock is subject to volatility, and there is no guarantee of price appreciation, potentially leading to substantial losses for investors.
• The company is a controlled company, with its CEO and Chairperson holding significant influence, which could lead to conflicts of interest.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to inaccurate financial reporting or fraud.

Future Outlook

The company's future outlook is impacted by its strategic shift to focus on quality control and channel optimization within its franchise network, which led to a decrease in the number of franchisees. The significant share-based compensation expense in FY2025 is not expected to recur at a similar magnitude. The company is also actively working to regain compliance with Nasdaq's minimum bid price requirement.

Management Comments

• The Company implemented enhanced franchisee admission criteria and more rigorous ongoing performance evaluation standards, focusing on improving the operational quality of existing franchisees rather than expanding the number of franchisees.
• The previous universal cash subsidy policy created a dependency among certain franchisees, and the subsidy payments were not effectively deployed toward service improvements or customer acquisition efforts.
• The Company retained the budget originally designated for cash subsidies and redirected it to its corporate-owned stores, as well as to investments in brand marketing and product research and development.
• The Company believes that its O2O Model has enabled it to reach a wider audience online, attract new customers, engage with customers across multiple channels, and increase sales while its customers can enjoy significant discounts and a seamless shopping experience.
• The Company's management concluded that its disclosure controls and procedures were not effective as of October 31, 2025, due to insufficient in-house personnel in the accounting department with sufficient knowledge of U.S. GAAP and SEC reporting rules.

Industry Context

StockSavvy.ai notes that Park Ha Biological Technology's performance in FY2025 reflects broader trends in the beauty and skincare industry in China, which is characterized by intense competition and evolving consumer preferences. The company's strategic pivot towards quality over quantity in its franchise model, coupled with increased investment in R&D and marketing, aligns with industry efforts to build brand loyalty and differentiate in a crowded market. However, the significant increase in G&A expenses due to share-based compensation and the Nasdaq compliance issues highlight the challenges faced by emerging companies in this sector, particularly those operating under complex regulatory environments.

Comparison to Industry Standards

• Competitors like Fanwenhua, DR PLANT, and Beauty Farm have over 100 franchisees nationwide, indicating a longer operating history and greater market share compared to Park Ha's 22 franchisees as of October 31, 2025.
• The beauty industry is highly competitive, with large multinational companies possessing greater financial, technical, and marketing resources, which can pose a challenge for Park Ha's market share.
• The company's gross profit margin on product sales to non-franchisees (96%) is significantly higher than that for sales to franchisees (78%), which is common in franchise models where franchisees add their own margins and bear operational costs.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any actions, claims, suits or other legal proceedings that management believes, if determined adversely, would individually or in the aggregate have a material adverse effect on its business, financial condition, and results of operations.

Related Party Transactions

• Advances were made to Ms. Xiaoqiu Zhang for working capital, with a balance of $35 as of October 31, 2025.
• Ms. Li Wang was owed $7,026 as of October 31, 2025, for a rent payment made on behalf of the company.

Stakeholder Impact

• Shareholders may experience substantial losses due to the volatility of the Ordinary Shares and the company's significant net loss in FY2025.
• The Nasdaq compliance issues could lead to delisting, impacting the liquidity and marketability of the Ordinary Shares.
• The significant increase in G&A expenses due to share-based compensation may dilute the value of existing shares.
• The company's strategic shift away from rapid franchise expansion and the discontinuation of cash subsidies to franchisees could impact franchisee relationships and future growth potential.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement.
• Continue to focus on quality control and channel structure optimization within the franchise network.
• Invest in brand marketing and product research and development.
• Expand directly operated stores in China using proceeds from recent offerings.

Key Dates

Recommendation

While the company shows growth in product sales and has improved its cash position, the significant net loss in FY2025, driven by a massive increase in G&A expenses due to share-based compensation, coupled with Nasdaq compliance issues and a shrinking franchise network, presents considerable risk. The strategic shift towards quality over quantity in franchising is a positive long-term move, but the immediate financial performance and listing concerns warrant a cautious 'hold' rating until there is clearer evidence of a turnaround and sustained operational improvement.

Keywords

Park Ha Biological Technology, SEC Filing, Form 20-F/A, Amendment, Financial Results, Net Loss, Revenue, Franchise Fees, Share-based Compensation, General and Administrative Expenses, Nasdaq Compliance, VIE Structure, China Regulations, Cybersecurity, Data Security, HFCAA, Delisting Risk, Credit Losses, Shareholder Equity, Cash Flow